Continuously growing numbers of multi-resistant bacteria form a massive threat in healthcare worldwide. The over-consumption of antibiotics births a new endemic disease where bacteria grow uncontrollably, causing infections that are hard to treat. ABIGO Medical addressed this challenge over 20 years ago by introducing a revolutionary wound dressing, Sorbact, which evolved into an entire family of products for advanced and effective wound management.
What makes Sorbact unique?
The entire product line, which consists of eleven different products is based on a unique technology. Unlike antimicrobial dressings that actively kill bacteria, Sorbact removes bacteria irreversibly binding them to its surface to reduce bioburden and support wound healing. Sorbact is not only highly effective against common wound bacteria including MRSA and VRE but also targets fungi. Sorbact does not release any active agents into the wound and development of bacterial or fungal resistance is not expected”, explains ABIGO Medical CEO Fredrik Stenbäcker.
Now a part of Essity
ABIGO Medical has continuously introduced new products to the Sorbact portfolio. This is still a continuous work in progress now that ABIGO Medical is part of the Essity Group since May 2021.
“Being part of a much larger organisation gives ABIGO Medical the strength and stability that we need in order to continue our journey as an innovative and growing company. Based on the Sorbact Technology, we are planning for further introductions of new, innovative solutions in the upcoming years”, reveals Fredrik Stenbäcker.
More to be done
Being able to treat wounds infections effectively and at the same time contribute within wound care to lower the use of antibiotics is an important step in order to overcome the accelerating problem with multi-resistant bacteria. ABIGO Medical is already one of the leading international companies in the field, but there is more to be done.
“ABIGO Medical has built up a strong knowledge base with skilled employees in various disciplines. The company has also built strong collaborations and not least established a culture that promotes development”, says Fredrik Stenbäcker, and continues:
“We will develop wound care of the future with the help of the established Sorbact Technology. As part of Essity, we represent a global leader in advanced wound management. We are proud that Sorbact today is helping patients in over 65 countries. We are also exploring business opportunities in the animal health market. There is more to be done and we will take a leading role”.